跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
HH-1-1
首页
药物
HH-1-1
HH-1-1
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Hybrid nano-materials HH-Cu, HH-2Cu and HH-3Cu with halogenase-like activity and laccase-like activity as well as preparation method and application of hybrid nano-materials HH-Cu, HH-2Cu and HH-3Cu
申请人: UNIV FUJIAN
优先权: 2023
CN
Combined nano-drug for enhancing ferroptosis and activating immune response as well as preparation method and application of combined nano-drug
申请人: WEST CHINA HOSPITAL SICHUAN UNIV
优先权: 2025
CN
一种UTR元件Hh及其构建方法和应用
申请人: 中国医学科学院医学生物学研究所
优先权: 2026
CN
Method for preparing antihuman lymphocyte antibodies
申请人: TAILIN WANG
优先权: 2009
CN
Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system
申请人: IVASHCHENKO ANDREY
优先权: 2007
US
2 件公开
COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF A DISEASE THAT IS ASSOCIATED WITH A WEAKENED INTESTINAL BARRIER
申请人: UNIV DER JOHANNES GUTENBERG UNIV MAINZ
优先权: 2023
EP
WO
2 件公开
STEREOSELECTIVE PH RESPONSIVE PEPTIDE DENDRIMERS FOR NUCLEIC ACID TRANSFECTION
申请人: UNIV BERN
优先权: 2019
CN
EP
US
WO
4 件公开
靶向Smo蛋白的Hedgehog信号通路抑制剂及制备方法和用途
申请人: 杭州医学院
优先权: 2021
CN
药物
反馈